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Abstract 24 
We demonstrate the application of a high-throughput modeling framework to estimate 25 
exposure to chemicals used in personal care products (PCPs). As a basis for estimating 26 
exposure, we use the product intake fraction (PiF), defined as the mass of chemical taken by 27 
an individual or population per mass of a given chemical used in a product. We calculated 28 
use- and disposal- stage PiFs for 518 chemicals for five PCP archetypes. Across all product 29 
archetypes the use- and disposal- stage PiFs ranged from 10
-5
 to 1 and 0 to 10
-3
, respectively. 30 
There is a distinction between the use-stage PiF for leave-on and wash-off products which 31 
had median PiFs of 0.5 and 0.02 across the 518 chemicals, respectively. The PiF is a function 32 
of product characteristics and physico-chemical properties and is maximized when skin 33 
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permeability is high and volatility is low such that there is no competition between skin and 34 
air losses from the applied product. PCP chemical contents (i.e. concentrations) were 35 
available for 325 chemicals and were combined with PCP usage characteristics and PiF 36 
yielding intakes summed across a demonstrative set of products ranging from 10
-8
 to 30 37 
mg/kg/d, with a median of 0.1 mg/kg/d. The highest intakes were associated with body 38 
lotion. Bioactive doses derived from high-throughput in vitro toxicity data were combined 39 
with the estimated PiFs to demonstrate an approach to estimate bioactive equivalent chemical 40 
content and to screen chemicals for risk. 41 
 42 
Keywords exposure modeling; personal care products; mass balance modeling; product 43 
intake fraction; risk screening; high-throughput  44 
 45 
1. Introduction 46 
There are potentially thousands of chemicals used in personal care products (PCP) and 47 
cosmetics (Egeghy et al., 2011) and estimating exposure to all these chemicals is not possible 48 
based on empirical techniques alone. Biomonitoring data, for example, are only available for 49 
a subset of compounds through programs such as NHANES (CDC, 2009) in the United 50 
States. Computational exposure models can be used to estimate chemical intake due to the 51 
use of PCPs based on physico-chemical properties, product composition, and product usage 52 
characteristics for chemicals in the absense of emperical data.  53 
There are several examples of high-throughput (HT) exposure models for chemical 54 
prioritization and screening (Wambaugh et al., 2013; Isaacs et al., 2014; Shin et al., 55 
2015).These HT exposure estimates are being combined with HT screening toxicity data, for 56 
example in vitro bioactivities from the U.S. EPA ToxCast program (Kavlock et al., 2012), to 57 
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screen and prioritize chemicals for risk (Cohen Hubal et al., 2010; Shin et al., 2015; Wetmore 58 
et al., 2015). These efforts have highlighted the need to better understand chemical exposure 59 
from consumer products (Wambaugh et al., 2013; 2014; Shin et al., 2015). PCPs are a 60 
product class for which emperical studies have found that usage is correlated with chemical 61 
exposures (Sandanger et al., 2011; Parlett et al., 2013). 62 
Jolliet et al.
 
(2015) have proposed the product intake fraction (PiF) metric to quantity the 63 
amount of chemical taken in by the exposed population per mass of chemical used in a 64 
consumer product. Shin et al. (2015) combined the PiF with chemical production volumes 65 
(PVs) to estimate dermal exposure to chemicals in PCPs using body lotion as a sentinel 66 
product. PVs, however, do not inform what proportion of the PV is used in any given product 67 
type or process nor on how many members of the population use a given chemical (Nazaroff 68 
et al., 2012; Shin et al., 2015). Dudzina et al. (2015) modeled route specific exposure 69 
fractions to PCP chemicals, however, this method was applied to a single chemical and has 70 
yet to be applied to several PCP chemicals at once. Recently, Csiszar et al. (2016) applied the 71 
PiF to estimate dermal and inhalation exposure to parabens in several PCP types using 72 
chemical fractional content (i.e., concentrations) with exposure estimates which compared 73 
well to biomonitoring data. The PiF can also be used to estimate environmentally mediated 74 
exposures to post-use emissions (referred to as disposal-stage) (Jolliet et al., 2015) although 75 
this has also yet to be performed in an HT study. 76 
In this paper, we combine PiFs with product usage and fractional chemical content data 77 
to develop an HT exposure and risk screening approach to estimate use- and disposal-stage 78 
exposures to hundreds of PCP-chemical combinations. The goals of this study are to: (i) 79 
demonstrate the use of PiF to estimate exposure to hundreds of PCP chemicals, (ii) 80 
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understand chemical and product specific factors affecting PiF, and (iii) within a risk 81 
screening context, use bioactive doses derived from in vitro screening toxicity data (Wetmore 82 
et al., 2012; 2015)  to demonstrate how bioactive chemical contents can be back-calculated 83 
and compared with actual chemical contents being used in PCPs (Goldsmith et al., 2014). 84 
2. Methods 85 
2.1 Product intake fraction for PCPs 86 
 We considered four exposure pathways for calculating PiF due to the application of 87 
PCPs to the skin. Dermal aqueous uptake (PiF
derm,aq
), inhalation (PiF
use,inh
), and dermal 88 
gaseous uptake (PiF
derm,g
), comprise the use-stage PiF and can be summed as PiF
use,tot
. The 89 
fourth pathway is an aggregated intake via outdoor environmental exposure pathways 90 
(PiF
disp
). The sum of all four pathways is PiF
tot
. Following Csiszar et al. (2016) and Ernstoff 91 
et al. (2016) for a product that is applied to skin, a mass-balance can be analytically solved to 92 
calculate the fraction of chemical lost from the product via transfer into the skin or 93 
volatilization to air (f
volat
). The fraction that is transferred to skin from the product is also the 94 
fraction of dermal aqueous uptake, i.e. PiF
derm,aq
 and the solution is  95 
     tkk
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where kps and kpa are the product-to-skin and product-to-air transfer rates (h
-1
), respectively, 97 
and t is the application duration (h) (see Supplementary Information (SI) for more 98 
information). The kps is a function of the aqueous skin permeation coefficient,
aq
pK  (m/h) 99 
which was calculated using the relationship of ten Berge (2009) based on molecular weight 100 
(MW) and octanol-water partition coefficient (Kow ). The kpa is a function of air-water mass 101 
transfer coefficient and depends on the air-water partition coefficient, Kaw. The fraction of 102 
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chemical that volatilizes to air becomes available for inhalation and gaseous dermal uptake 103 
and transfer to outdoor air. We assumed that chemicals volatilize to a near-person area of 1 104 
m
3
 (Isaacs et al., 2014) and then transfer to a larger well-mixed indoor air compartment. 105 
After the exposure duration, t, the fraction of chemical remaining in the applied product (i.e., 106 
on the skin surface) is assumed to be washed down the drain to a waste water treatment plant 107 
(WWTP) resulting in subsequent fractions emitted to air, water, and soil. To estimate PiF
disp
 108 
we multiplied the emission fractions to WWTPs and outdoor air with their respective outdoor 109 
mediated intake fractions (mass of chemical taken in per mass of chemical emitted) for 110 
release to air, water, and soil calculated using the USEtox model (Rosenbaum et al., 2008). 111 
These processes are summarized in Figure S1 and equations are listed in Tables S1 and S2 in 112 
the SI.  113 
Product and exposure characteristics (i.e., irrespective of chemical properties) which 114 
determine the PiF include product use duration, product thickness, room ventilation rates, 115 
inhalation rates, and surface area of skin in contact with air (Csiszar et al., 2016). Product 116 
characteristics were grouped into five different product archetypes: ‘leave-on’; ‘leave-on, 117 
spray’; ‘shampoo’; ‘body wash’; ‘face wash’; with distinguishing parameters summarized in 118 
Table S3 and based on Csiszar et al. (2016). Incidental ingestion, for example, from hand-to-119 
mouth contact can also be an exposure pathway for PCP chemicals. We did not model this 120 
pathway for most products since we assumed that it was negligible for wash-off products and 121 
small compared to dermal uptake for leave-on products. This pathway is likely most 122 
important for products with lip application. To address this, we included a 1% ingestion of 123 
product irrespective of chemical properties (Isaacs et al., 2014) and the remaining 99% 124 
treated as the ‘leave-on’ archetype. This method or more elaborate hand to mouth models 125 
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based on contact frequency could also be used to include incidental ingestion for other 126 
product types, especially for chemicals which have small PiFs for the other considered 127 
pathways. 128 
2.2 Intake and risk screening  129 
The PiF can be combined with chemical content and product use information to estimate 130 
chemical intakes following Csiszar et al. (2016). The intake (mg/kg/d) of a chemical, c, due 131 
to the use of a single PCP, p, can be calculated as 132 
 
BW
PiFfP
I
tot
pcpcp
pc
,,
,             (2) 133 
where Pp is the mass of product p used per person per day (mg/d) , fc,p is the fractional 134 
chemical content in a given product, and BW (kg) is body weight. In this paper, aggregate 135 
PCP exposure to one chemical refers to the sum of intakes across the eleven products types 136 
that chemical was found to be used in (referred to as relevant product types) and calculated as  137 

p
tot
pcpcpc PiFfP
BW
I ,,
1
 .          (3) 138 
If mean population level aggregate intakes are required, intakes can be adjusted for the 139 
fraction of the population using a given PCP and the prevalence of a chemical in a given PCP 140 
as suggested by Cowan-Ellsberry and Robison (2009). In this study, the occurrence of a 141 
chemical in a given product type was accounted for by only considering product-chemical 142 
combinations derived from the U.S. EPA Consumer Product Chemical Profile database 143 
(CPCPdb) (Goldsmith et al., 2014). To obtain a range of both single product and aggregate 144 
intakes we used mean, minimum, and maximum values of fc,p  across a given product type 145 
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and the mean, 10
th
, and 95
th
 percentiles of Pp  (Loretz et al., 2005; 2006; 2008) and refer to 146 
these as mean, low, and high intakes, respectively.  147 
We back-calculated bioactive equivalent chemical contents, BEC , that is, chemical-148 
specific PCP content which would yield a biological response based on PiF-estimated 149 
exposures.  These can be based on toxicity metrics, such as minimum oral equivalency doses 150 
(OEDs) derived from in vitro screening toxicity data (Wetmore et al., 2012; 2015) which 151 
have been used previously to screen chemicals for risk (Shin et al., 2015). The intake 152 
equation (Eq. 3) can be re-arranged to solve for fractional BECc, and by replacing intake, Ic 153 
with an OEDc (mg/kg/d) as 154 



p
tot
pcp
c
c
PiFP
BWOED
BEC
,
 .          (4) 155 
This BECc represents the bioactive concentration assuming that intake is aggregated across 156 
PCPs and thus represents an average chemical content within each PCP considered in the 157 
sum and is not product specific. We considered two distinct scenarios to calculate a range in 158 
BECc. For a given chemical, we assumed that an individual used all products in which the 159 
chemical was found to occur (i.e. relevant products) and a second hypothetical situation 160 
where a user is exposed to this chemical via all 11 considered PCPs.  Additionally, we used 161 
the 95
th
 percentile Pp from Loretz et al. (2005, 2006, 2008), to model a “high-use” individual 162 
using all PCPs in high amounts. To screen for potential risks, BECs were compared 163 
toreported chemical contents.(Goldsmith et al., 2014) 164 
2.3 Identifying Chemicals used in PCPs 165 
Chemicals used in PCPs were identified using the U.S. EPA CPCPdb  (Goldsmith et al., 166 
2014) which provides product specific chemical contents. The products in the CPCPdb were 167 
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mapped to product categories used in the U.S. EPA SHEDS-HT consumer product exposure 168 
model (Isaacs et al. 2014, personal communication) and these categories were used to 169 
identify chemicals and associated contents used in PCPs. The chemical list was additionally 170 
filtered based on availability of chemical properties in EPISuite (U.S. EPA, 2012) and falling 171 
within the applicability range of the 
aq
pK  relationship (logKow: -4 to 6; MW: 10 to 1000 172 
g/mol) (ten Berge, 2009) yielding a total of 518 chemicals. This list of chemicals was used to 173 
calculate PiFs for a range of chemicals that could be used in PCPs.  174 
To demonstrate chemical intake calculations, the amount of PCP used is needed as well 175 
as information on the chemical concentrations in those products (Equation 2). For these 176 
demonstrative calculations, we chose a subset of eleven commonly used PCPs (body lotion, 177 
body wash, conditioner, deodorant, eye shadow, face cleanser, face cream, foundation, 178 
lipstick, perfume, shampoo) with readily available product mass usage information for the 179 
US female population (Loretz et al., 2005; 2006; 2008) (Table S5), a population group with 180 
wide PCP usage (Wu et al., 2010; Biesterbos et al., 2013). The SHEDS-HT product 181 
categories (Isaacs et al., 2014) were mapped to these eleven categories and were assigned 182 
each of the eleven product categories to one of the five PiF archetypes (Table S3) to calculate 183 
product specific PiFs. Several product-chemical combinations did not have specific fractional 184 
chemical contents thus limiting the number of chemicals with chemical content information 185 
to 325 (i.e. these chemicals had at least one product with a reported concentration). These 186 
chemicals were used to demonstrate intake estimates. Of these 325 chemicals, in some cases, 187 
a chemical was identified as occurring in a specific product type without concentration 188 
information for that specific product type; in these cases we used the average chemical 189 
content for that chemical across the other PCP types (Table S6).  190 
 9 
 
3. Results 191 
3.1 PiFs for PCP chemicals 192 
We calculated PiFs for the 518 chemicals for all five PCP archetypes. Across all 193 
archetypes the use- and disposal- stage PiFs ranged from 10
-5
 to 1 and 0 to 10
-3
, respectively. 194 
The wash-off archetypes had the largest PiF
disp
 values and for most chemicals the use-stage 195 
PiF was several orders of magnitude larger than the disposal-phase PiF, however, ~35% of 196 
chemicals had PiF
disp 
values within an order of magnitude of PiF
use,tot 
(for the shampoo 197 
archetype). For these chemicals, however, the largest PiF
tot
 was 0.006 indicating that when 198 
PiF
use
 and PiF
disp
 have similar values, the total PiF is relatively small compared to other 199 
chemicals which can have PiF
tot
 up to unity. The PiF
use
 for the leave-on product archetype 200 
was at least an order of magnitude larger than PiF
disp 
for all chemicals. It follows that 201 
individual exposure to most PCP chemicals is generally dominated by the use-stage 202 
(especially for leave-on products) rather than the disposal stage once a chemical has been 203 
emitted outdoors. This is supported by studies which have found correlations between PCP 204 
usage and measured levels of chemicals such as phthalates and parabens in urine (Sandanger 205 
et al., 2011; Parlett et al., 2013; Harley et al., 2016). 206 
The cumulative distributions of the use-stage PiF dermal and inhalation routes for the 207 
518 chemicals can be found in Figure 1. The dermal uptake route dominates the PiF
use,tot
 for 208 
all archetypes. The maximum PiF
use,inh
 is bounded by the inhalation intake fraction (iF) 209 
estimated approximately as the ratio of the inhalation rate (IR) to the air ventilation rate (VR) 210 
(see discussion in the SI) (Figure S2). While there is considerable uncertainty in the 211 
inhalation iF which was bounded by approximately 0.04, it is similar to the indoor iF of 0.01 212 
 10 
 
as estimated by Hellweg et al. (2009). Combining the inhalation intake fraction and the 213 
fraction volatilized results in a limited contribution of PiF
use,inh
 to PiF
use, tot
. 214 
 There is a clear distinction between the PiF
use,tot
 for leave-on versus wash-off products 215 
with medians across the 518 chemicals of 0.5 and 0.02 for the ‘leave-on’ and ‘shampoo’ 216 
archetypes, respectively. The ‘leave-on, spray’ category yielded a similar PiFuse,tot cumulative 217 
distribution to the ‘leave-on’ products as both categories had median PiFuse,tot of 0.5, resulting 218 
from the limited contribution of PiF
use,inh
 described above. Of the three wash-off archetypes 219 
the ‘body wash’ category yielded the highest PiFuse,tot values due to the larger surface area of 220 
application (Eq. 1, Table S3) (Csiszar et al., 2016).  221 
 222 
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  223 
 224 
Figure 1: Cumulative distributions of the 518 PCP chemicals for the five PCP archetypes for 225 
the a) dermal PiF (PiF
derm,aq 
+ PiF
derm,g
) and PiF
use,inh
, and b) PiF
use,tot
.  226 
  227 
3.2 PiF and chemical properties 228 
In this model, the PiF
use,tot
 depends on three physico-chemical properties: Kaw, and 229 
Kow and molecular weight (MW), primarily via the 
aq
pK relationship. To understand how 230 
properties mediate PCP exposure during use we plotted the use-stage PiF as a function of log 231 
aq
pK  (which is a function of Kow and MW) and log Kaw at the median MW (195 g/mol) for the 232 
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two most distinct archetypes of ‘leave-on’ and ‘shampoo’. The PCP chemicals in this paper 233 
cover a wide range of properties (log Kaw: -42 to 2.6; log 
aq
pK (cm/h) –5.4 to 0.6) (Figure 2).   234 
Equation 1 and Figure 2 demonstrate PiF
derm,aq
 is maximized when skin permeability 235 
is high and volatility is low such that there is no competition between skin and air losses 236 
from the applied product. For the ‘leave-on’ archetype, we can distinguish three main zones: 237 
at low Kaw (i.e., < 10
-8
, ~40% of the considered chemicals) where volatilization of the applied 238 
product is small compared to dermal uptake and wash-off. For most chemicals, PiF
derm,aq
 and 239 
therefore PiF
use,tot
 are high (i.e. close to 1) and it is only for very low 
aq
pK  (i.e. < ~10
-5 
cm/h) 240 
and for a few of the considered chemicals that PiF
use,tot 
was less than 0.5.  241 
In the intermediary zone, (-8 ≤ log Kaw ≤ -3, ~40% of the considered chemicals) 242 
volatilization competes with dermal uptake, which is reflected by diagonal projected in the 243 
Kaw/
aq
pK  space. (Figure 2a).This demonstrates the importance of using a mass balance model 244 
that accounts for the competition between the different exposure routes. Overall the PiF 
use,tot
 245 
decreases with increasing Kaw as PiF
use,inh
 is limited by the indoor intake fraction, whereas 246 
PiF 
derm,aq
 is closer to 1 at higher 
aq
pK . For a subset of properties, the PiF
derm,g 
can be larger 247 
than PiF
use,inh
 for chemicals which readily volatilize from an aqueous solution, however, also 248 
partition favorably from air to skin. This has also been found by Weschler and Nazaroff 249 
(2014) for several chemicals.  250 
At high Kaw (i.e. >10
-3
, ~20 % of the considered chemicals), volatilization 251 
substantially contributes to the removal of chemical applied to skin and limits the PiF
derm,aq
, 252 
even at high 
aq
pK . For the chemicals considered in this study, PiF 
use,tot
 was bound ~0.5 in 253 
this zone.  254 
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Overall, for the ‘leave-on’ archetype, this leads to ~50% of chemical with PiF use,tot 255 
greater than or equal to 0.5 dominated by dermal uptake, and ~10% with PiF 
use,tot
 less than 256 
~0.04 dominated by inhalation. The remaining ~40% are intermediate chemicals for which 257 
both volatilization and dermal uptake are of similar importance in terms of ingredient 258 
removal and exposure.  259 
The ‘shampoo’ archetype follows similar patterns, however, generally with a 260 
substantially higher fraction washed-off due to the shorter exposure time (i.e. on the order of 261 
minutes compared to hours), which limits the dermal uptake, especially at low
aq
pK . Reducing 262 
the exposure duration also reduces the exposure potential for most property combinations. 263 
However, for chemicals with relatively fast skin permeability values (e.g. ~ 1 cm/h), dermal 264 
uptake reaches plateau often within just a few minutes. Thus, reducing the exposure duration 265 
for high skin permeability compounds does not generally decrease the PiF 
use,tot
. Of the 518 266 
chemicals studied, only a small subset fell into this category (Figure 2). Nevertheless, of 267 
these few chemicals some are matched to uses in over 100 PCPs suggesting their use can be 268 
common. Additionally, for chemicals with relatively low ‘leave-on’ PiFuse,tot (e.g. < 0.1), 269 
reducing exposure duration can also yield PiFs within a factor of one between the exposure 270 
scenarios; this also occurred for a subset of chemicals as shown on Figure 2.” 271 
 272 
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 273 
Figure 2:. The use-stage log10 PiFs as a function of log10 Kow and log10 
aq
pK (cm/h) for a) 274 
‘leave-on’ and b) ‘shampoo’ product archetypes at the median molecular weights of the PCP 275 
chemicals. The plot of log PiF
use,tot
 includes the Kaw and 
aq
pK values from the PCP chemicals 276 
in this study as black dots.  277 
Notes: The molecular weights of the chemicals also vary, such PiF
use,tot
 values on this plot 278 
are approximate for the actual chemicals. Some chemicals had properties which did not fall 279 
within the values of these demonstrative plots and were thus not included in the figure. 280 
 281 
 282 
3.3 Mass applied and chemical intakes  283 
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Across the 325 chemicals, mean PCP content ranged from 10
-6
 – 55 % (low: 10-6 – 284 
51%, high: 10
-6
 – 100%), yielding masses of chemical applied ranging from 10-8 – 250 285 
mg/kg/d (low: 10
-9
 – 66 mg/kg/d; high: 10-8 – 680 mg/kg/d) aggregated over the relevant 286 
products. The aggregated mass applied across the considered products was dominated by the 287 
wash-off products conditioner, body wash, and shampoo and the leave-on product body 288 
lotion (Figure 3a). Applying PiF
tot
 to the mass of chemical applied (to each product) reduced 289 
the  intake aggregated across products by two orders of magnitude on average (range: factor 290 
of 1 to 10
4
). The mean chemical intake aggregated across the product types ranged from 10
-8
 291 
– 30 mg/kg/d (low: 10-9 – 8 mg/kg/d; high:  10-8 – 85 mg/kg/d) across the 325 chemicals, 292 
with the highest intakes associated with body lotion (Figure 3b).  293 
 294 
Figure 3: Ranges in a) mean mass of chemical applied, i.e. mean product mass applied 295 
multiplied with mean chemical content, and b) intake doses after applying the PiF
tot
 across 296 
the 325 chemicals with intake estimates. The “SUM” column refers to doses aggregated over 297 
the eleven products for each chemical.  298 
 299 
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Fourteen of the PCP chemicals assessed here also had screening intakes estimated by Shin et 300 
al. (2015) using PVs and the PiFderm,aq assuming a body lotion archetype. We verified that 301 
these chemicals are used in PCPs by checking that they appear in other databases (U.S. NIH, 302 
2015) (Dionisio et al., 2015) as having PCP use. After this, one chemical was removed from 303 
the list resulting in 13 chemicals for the analysis. For seven of the chemicals, the mean mass 304 
of chemical applied and estimated intakes (aggregated across products) in this paper were 305 
larger than those using the methods of Shin et al. (2015) (Figure S3). For three of these 306 
chemicals (ethyl-, propyl, and butyl-paraben), there was no overlap between estimates in this 307 
paper and those using the methods of the Shin et al (2015) (Figure S3b). Csiszar et al. (2016) 308 
estimated intake distributions for parabens, also using product content as input (rather than 309 
PVs), and found that the estimated exposures agreed well with biomonitoring data.  The 310 
mean paraben intakes of Csiszar et al. (2016) were also higher than those estimated by Shin 311 
et al. (2015) (Figure S3b) indicating that using PVs may in certain cases underestimate mass 312 
applied and therefore chemical exposure due to PCP usage. This may be especially relevant 313 
for chemicals such as parabens that are mostly used in PCPs, and when assuming that an 314 
individual is exposed via all considered PCPs.  315 
3.4 Bioactive equivalent chemical contents and risk screening 316 
   Of the chemicals with estimated intakes there were 18 which also have OEDs, 317 
derived from in vitro toxicity data (Wetmore et al., 2012; Shin et al., 2015; Wetmore et al., 318 
2015). We removed one chemical from this list (resulting in 17 chemicals) as we verified 319 
that these chemicals are used in PCPs as described for the comparison to Shin et al. (2015). 320 
For these chemicals, we back-calculated bioactive equivalent chemical contents (BECs) by 321 
assuming that a given chemical occurs in either each of the 11 product types or only in the 322 
 17 
 
relevant product types (i.e. those that were found to contain a given chemical derived from 323 
the CPCPdb). This yielded ranges in back-calculated BECs of ~10
-4
 – 16% and ~10-3 – 324 
100%, respectively. For 6 of the 17 chemicals, the mean  chemical content derived from the 325 
CPCPdb was higher than the back-calculated BEC for the relevant product types and four 326 
more were within a factor of ten of the mean  chemical content (Figure 4). Assuming that a 327 
given chemical occurred in all versus relevant product types decreased the back-calculated 328 
BECs by up to two orders of magnitude. Comparing BECs calculated assuming chemical 329 
occurrence in all product types, to the maximum chemical contents derived from the 330 
CPCPdb indicated that all but one of the chemicals were within a factor of ten of the BEC. 331 
While this analysis was only conducted for a small subset of chemicals it demonstrates how 332 
the PiF can be used with bioactive doses to calculate bioactive chemical contents and to 333 
screen chemicals for risk.  334 
 18 
 
 335 
Figure 4: Back-calculated bioactive equivalent chemical contents (BECs) assuming that a 336 
given chemical is used in a) only relevant PCPs (i.e. those PCPs in which the chemical 337 
appeared, derived from Goldsmith et al. (2014)) and b) all 11 considered PCPs; and 338 
comparison with c) mean chemical content found in the considered PCPs derived from 339 
Goldsmith et al. (2014). The error bars represent the mean of the low and high content across 340 
the considered PCP types; some chemicals did not have ranges available and thus do not 341 
have error bars.      342 
 343 
4. Discussion  344 
 We demonstrated how the PiF can be used to rapidly estimate exposure potentials for 345 
chemicals in PCPs. The PiF models used in this study allowed estimation of multi-pathway 346 
exposures which accounted for the transfer fractions, for example, from skin to air. This 347 
method also allows for estimating exposure due to outdoor releases associated with product 348 
use, thereby coupling near-field chemical release fate and exposure with far-field ones. The 349 
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plots of PiF as a function of chemical properties give insight into properties which mediate 350 
exposure (Figure 2). For example, Figure 2a demonstrates that for low volatility chemicals 351 
(i.e. Kaw less than 10
-8
), exposure potential is driven by the skin permeability of the chemical; 352 
and for leave-on products, low values of 
aq
pK   (e.g. < ~10
-5
 cm/h) were needed to yield 353 
PiF
use,tot
 values less than 0.5. As Kaw increases, dermal permeability and volatility become 354 
competing processes influencing exposure potentials. An understanding of the effects of 355 
chemical properties on the PiF could potentially inform the design or choice of chemicals in 356 
PCPs to minimize exposure potential. 357 
 There was a clear distinction between the use-stage PiFs for leave-on compared to 358 
wash-off products (Figure 1), suggesting that for HT purposes, it may only be necessary to 359 
distinguish between either a ‘leave-on’ or ‘wash-off’ product when calculating a PiF rather 360 
than further distinguishing between product use scenarios. Applying the PiF to hundreds of 361 
PCP chemicals indicated that the use-stage PiF dominates chemical intake for most product-362 
chemical combinations, but not necessarily for all. Furthermore, there are members of the 363 
population who are not exposed to a given chemical in the use-stage (i.e. they do not use 364 
PCPs containing specific chemicals) thus their exposure would only occur from outdoor 365 
chemical releases. This indicates that intakes due to outdoor releases should also be included 366 
in exposure assessments, especially for wash-off products with the largest PiF
disp
 values.  367 
   Chemical contents within a given PCP type varied over several orders of magnitude 368 
yielding a large variation in applied doses, however, this variability could be lessened when 369 
comparing across chemicals with similar function as they may have similar chemical 370 
properties (Egeghy et al., 2015). For leave-on products there is a much smaller variation in 371 
PiF across products than there is in chemical content, however, applying the PiF can still 372 
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change estimated intakes by an order of magnitude. This suggests that for leave-on products 373 
the PiF may have a smaller contribution to overall exposure than product chemical content 374 
data. For rinse-off products, on the other hand, the variation in PiF and content are of similar 375 
orders of magnitude indicating that both these terms can contribute substantially to final 376 
estimated intake doses. 377 
Comparing our results to those of Shin et al. (2015) indicates that using PVs may not 378 
necessarily provide the most conservative screening level exposures, highlighting the 379 
importance to apply product content-based approaches. However, there is limited data 380 
available on chemical contents in products (not just PCPs) which are needed to estimate 381 
intakes (Egeghy et al., 2012); for example in this study, intakes were estimated for 325 of the 382 
chemicals that had chemical content data available, among the 518 PCP chemicals with 383 
estimated PiFs.  Forthcoming efforts to estimate chemical contents in products will aid in 384 
increasing the amount of chemicals for which screening level exposures can be estimated 385 
(Egeghy et al., 2015).  386 
We also demonstrated the use of the PiF and in vitro bioactivity data to estimate 387 
bioactive chemical contents. Comparing these values derived from the CPCPdb indicates that 388 
some users may be exposed to PCP chemicals at bioactive levels. In this study we only 389 
considered PCPs, however the Chemical and Product Categories (CPCat) database (Dionisio 390 
et al., 2015) indicates that all of these chemicals are also used in other product classes (e.g. 391 
household cleaners, building materials, etc.) such that exposure to PCPs may not represent all 392 
sources of exposure. Identifying all products in which a chemical occurs is needed to carry 393 
out chemical-specific aggregate exposure assessments and to identify bioactive chemical 394 
levels across product types and classes. 395 
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The model presented here provides a simple analytical solution which can be used in 396 
HT exposure calculations and depends on physico-chemical properties which can be 397 
estimated for many chemicals using software such as EPISuite (U.S. EPA, 2012). The model, 398 
however, involves several assumptions. For example, we assumed that PCPs represent an 399 
aqueous solution and studied one chemical at a time, but other ingredients within a product 400 
could alter the skin permeability of the chemical from the product to the skin. We also used 401 
limited data to estimate the near-person inhalation during product use and further research 402 
may be needed to model this exposure pathway, especially for volatile chemicals. Several 403 
chemicals used in PCPs may have physico-chemical properties which cannot be readily 404 
estimated or applied to the 
aq
pK  model, for example ionogenics and nanomaterials, both 405 
chemical classes which can be used in PCPs (Csiszar et al., 2011; Weir et al., 2012). As with 406 
all mass-balance based exposure models that take physico-chemical properties as input, there 407 
will be uncertainties associated with using these values. The PCP model in this paper 408 
depends on Kaw and Kow, which have uncertainties associated with them, especially when 409 
using estimated values. Figure 2a indicates, that for the ‘leave-on’ archetype (highest 410 
exposure scenario), the model is likely most sensitive to property values when there is 411 
competition between transfer to air and skin (diagonal on Figure 2a). The model will be less 412 
sensitive at the high- or low- ends of physico-chemical properties, for example, when log Kaw 413 
is small (e.g. < -10) PiF
use,tot
 approaches unity and is thus relatively insensitive to decreases 414 
in Kaw (Figure 2a). Figure 2b indicates that for wash-off products, PiF
use,tot 
is more sensitive 415 
to physico-chemical properties as there is a more heterogeneous distribution of PiF
use,tot
, due 416 
to the shorter exposure duration. For the chemicals in this study, 129 and 196 chemicals had 417 
both experimental and estimated log Kaw and log Kow values, respectively, which on average 418 
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differed by a factor of ~1.5 (experimental values were used in this study, when available). 419 
However, the discrepancy between measured and estimated properties was substantially 420 
larger for some chemicals, thus care should be taken when interpreting results when 421 
estimated properties are used. 422 
Additionally, uncertainty can also occur based on which exposure pathways are 423 
included in the assessment. For example, we only included incidental ingestion for 424 
application to lips. For other leave-on products, this pathway may be important for chemicals 425 
with low volatility and skin permeability as these chemicals would remain on the skin surface 426 
longer and would thus be available for ingestion via, for example, hand-to-mouth behavior. 427 
Thus, in the context of prioritizing chemicals, it may be as important to screen not only for 428 
high exposure potentials, but also very low ones to make sure a pathway was not missed. The 429 
modeling framework presented here can be extended to include other exposure pathways. 430 
Recently, Fantke et al. (2016) proposed a matrix framework to calculate PiFs via several 431 
pathways designed with the flexibility to add pathways as needed or as more information 432 
becomes available about important exposure pathways. While calculations in this paper were 433 
deterministic, there can be considerable population variability in doses due to differences in 434 
factors such as individual PCP use and these calculations can also be done probabilistically to 435 
estimate population level exposure distributions (Csiszar et al., 2016). Uncertainty and 436 
variability in values can be taken into account for higher tier exposure estimates (Embry et 437 
al., 2014).    438 
While the focus of this paper is to estimate human exposure to PCP chemicals, the 439 
use-stage PiF can also be used to inform chemical emission estimates to outdoor 440 
environments. For example, we also calculated the fraction of chemical emitted to urban air 441 
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and to WWTPs and multiplying this by the mass of chemicals used in PCPs would yield 442 
outdoor emission estimates for these chemicals due to PCP use. Estimating environmental 443 
PCP chemical emissions has garnered interest as PCP chemicals have been detected in 444 
surface waters (Brausch and Rand, 2011; Gouin et al., 2013) and can potentially harm 445 
organisms and ecosystems. The percentage of applied chemical emitted to outdoor air and 446 
WWTPs both ranged from 0 to ~100% and was highly dependent on the fractional amount of 447 
chemical that the individual user is exposed to. Considering environmental releases is also 448 
key when comparing human health impacts with ecological impacts such as those on aquatic 449 
ecosystems within broader chemical assessments.  450 
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